Cited 0 times in
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승일 | - |
dc.contributor.author | 김지예 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박정민 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 최순보 | - |
dc.contributor.author | 안지현 | - |
dc.date.accessioned | 2021-11-19T01:42:07Z | - |
dc.date.available | 2021-11-19T01:42:07Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/185988 | - |
dc.description.abstract | Hormone receptor (HR)-positive breast cancer has a heterogeneous pattern according to the level of receptor expression. Patients whose breast cancers express low levels of estrogen receptor (ER) or progesterone receptor (PgR) may be eligible for adjuvant endocrine therapy, but limited data are available to support this notion. We aimed to determine whether HR expression level is related to prognosis. Tumors from 6042 patients with breast cancer were retrospectively analyzed for combined HR levels of ER and PgR. Low expression was defined as ER 1-10% and PgR 1-20%. Four HR groups were identified by combining ER and PgR expression levels. Patients whose tumors expressed high levels of a single receptor showed the worst survival outcomes, and their risk continuously increased even after the 10-year follow-up. Endocrine therapy had a significant benefit for patients whose tumors expressed high HR levels and a favorable tendency for patients with tumors expressing low HR levels. We established the possible benefit of endocrine therapy for patients whose breast tumors expressed low HR levels. Thus, HR level was a prognostic factor and might be a determinant of extended therapy, especially for patients with high expression of a single receptor. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Jee Hyun Ahn | - |
dc.contributor.googleauthor | Soon Bo Choi | - |
dc.contributor.googleauthor | Jung Min Park | - |
dc.contributor.googleauthor | Jee Ye Kim | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Byeong-Woo Park | - |
dc.contributor.googleauthor | Seho Park | - |
dc.identifier.doi | 10.3390/cancers13195007 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A00984 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A06148 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A05769 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 34638491 | - |
dc.subject.keyword | breast cancer | - |
dc.subject.keyword | endocrine therapy | - |
dc.subject.keyword | estrogen receptor | - |
dc.subject.keyword | gene expression | - |
dc.subject.keyword | neoplasms by histologic type | - |
dc.subject.keyword | progesterone receptor | - |
dc.subject.keyword | survival analysis | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | 김승일 | - |
dc.contributor.affiliatedAuthor | 김지예 | - |
dc.contributor.affiliatedAuthor | 박병우 | - |
dc.contributor.affiliatedAuthor | 박세호 | - |
dc.contributor.affiliatedAuthor | 박정민 | - |
dc.contributor.affiliatedAuthor | 박형석 | - |
dc.contributor.affiliatedAuthor | 최순보 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 19 | - |
dc.citation.startPage | 5007 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.13(19) : 5007, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.